Larvol Delta - Ault-Alliance-Announces-Alzamend-Neuro-Has-Initiated-Its-Phase-IIIA-Trial-for-Its-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimers-Type

ALZN002 - Alzamend Neuro

https://www.businesswire.com/news/home/20230404005575/en/Ault-Alliance-Announces-Alzamend-Neuro-Has-Initiated-Its-Phase-IIIA-Trial-for-Its-Immunotherapy-Vaccine-ALZN002-to-Treat-Mild-to-Moderate-Dementia-of-the-Alzheimer%E2%80%99s-Type

Apr 4, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next